Whalesbook
FY26 Performance: Revenue Dip Amid Global Pressures
Piramal Pharma concluded fiscal year 2025-26 with a 3% revenue decrease and a 28% EBITDA contraction. This performance was impacted by external pressures, including geopolitical tensions in West Asia and reduced biotech funding. The company’s contract development and manufacturing organization (CDMO) segment saw a 10% revenue reduction for the fiscal year. The second half of FY26, however, showed a recovery in momentum, supported by increased US biotech funding and sector deal activity. As of April 2026, Piramal Pharma’s stock had a P/E ratio of 30.54, reflecting investor expectations for future profitability. The company’s market capitalization was approximately ₹21,710.60 crore.
Supply Chain Pressures and Piramal's Response
Geopolitical instability in West Asia is affecting input costs, especially for petrochemical-derived materials like natural gas, diesel, and solvents. Raw material costs for key pharmaceutical ingredients have reportedly surged by as much as 200-300% in short periods. Piramal Pharma is implementing a strategy to address these pressures. This involves diversifying sourcing to reduce reliance on single regions or suppliers and utilizing its global manufacturing network. There's also growing interest in onshoring production, particularly at its US and UK facilities, as companies prioritize supply chain security. The Indian government has introduced measures, including a customs duty exemption on certain petrochemical products until June 2026, to help stabilize supplies and lower input costs for domestic industries.
Driving Growth: CDMO Recovery and New Business Areas
Looking to fiscal year 2026-27, Piramal Pharma forecasts early- to mid-teens revenue growth and improved EBITDA. This expansion is expected to come from operating leverage, scaling its international manufacturing sites, and a recovery in CDMO order inflows. The broader global CDMO market is projected to grow significantly, driven by demand for biologics and advanced therapies. Piramal is focusing on specialized areas like antibody-drug conjugates (ADCs) and highly potent active pharmaceutical ingredients (HPAPIs). The complex hospital generics business is set for growth, boosted by the recent Kenalog acquisition and increased inhalation anaesthesia sales in markets outside the US. The consumer healthcare business is also expected to grow, supported by its 'power brands' and expansion in e-commerce channels.
Industry Overview and Piramal's Position
The Indian pharmaceutical sector is expected to see steady growth, with revenues projected to expand by 7-9% in FY26, driven by domestic demand and stable exports. The global CDMO market is also growing, fueled by increased outsourcing and the expansion of biologics. Piramal Pharma's P/E ratio of 30.54 is in line with other Indian pharmaceutical companies, though peer valuations vary. Competitors like Syngene International trade at a lower valuation with a target price around ₹613, while Laurus Labs is considered overvalued with a target of approximately ₹974. Piramal Pharma’s stock performance has lagged behind benchmarks over the past year.
Analyst Views and Key Risks
Analysts generally maintain a positive view, with a consensus rating of 'Strong Buy' and an average 12-month price target around INR 200.10 to INR 228.33, suggesting a potential upside of over 20%. However, potential risks warrant scrutiny. The FY26 financial results, including a 28% EBITDA decline and a 3% revenue drop, show the company’s vulnerability to external shocks. While the stock currently shows a P/E of 30.54, past periods have seen negative P/E ratios, which could concern investors if the projected turnaround falters. A significant impairment loss of ₹176 crore in FY26 related to intangible assets under development also highlights potential challenges. Dependence on volatile US biotech funding and risks in scaling global operations and integrating acquisitions add to concerns. Intense competition in the CDMO sector, where integrated services are becoming standard, also presents a challenge. Despite these risks, Piramal Pharma has guided for early- to mid-teens revenue growth with improved EBITDA margins for FY27, driven by operating leverage, scaling international sites, and CDMO order recovery. Earnings growth is projected substantially, with an anticipated annual increase of 121.1% and revenue growth of 13.2% per annum.